Provider review
HealthRX review
Independently certified, with a rare oral tablet beside the injections.
A verifiable certification number plus a tablet route, against pricing that is company-stated rather than live-verified.
Price as published
Compounded GLP injectable ~$189/mo · oral GLP tablet ~$239/mo · GLP+GIP ~$349/mo (company-stated)
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The verdict
HealthRX carries a LegitScript certification with a number you can check, which is a harder trust signal than most compounders on this board offer, and it lists an oral GLP tablet alongside the standard injectables — a needle-free route for someone who wants to take a small amount. Its monthly pricing is transparent in structure and does not stack a membership underneath. The reason to be careful is provenance: several tiers are company-stated against a relatively thin public site, and the states it serves are not published, so treat the figures as provisional and confirm eligibility first.
The trade-off we would want you to read first
Several tiers are company-stated against a relatively thin public site, so treat the figures as provisional
Who it suits, and who it does not
A good fit if
- A checkable certification number matters to you more than brand recognition
- You want a tablet route rather than an injection
- You want monthly pricing without a membership underneath it
Look elsewhere if
- You want figures you can confirm on a live checkout before committing
- You need published state availability before you start
- You want an in-house brand-name programme rather than a pass-through
How the programme works
HealthRX is a LegitScript-certified (#50087439) physician-supervised telehealth practice for medical weight loss. A licensed-provider intake gates access, then compounded semaglutide or tirzepatide is dispensed from US pharmacies at transparent monthly pricing with no insurance required. It is one of the few programs to carry a rare oral GLP tablet alongside injectables. Company-stated pricing runs roughly $189/mo for the compounded GLP injectable, ~$239/mo for the oral tablet, and ~$349/mo for a GLP+GIP tier. The microdose-relevant angle is transparent, low-dose-friendly monthly pricing rather than membership-stacked billing.
At a glance
- Pricing structure
- Varies by dose, plan or tier
- Consult
- Included in the price
- Compounding
- Not publicly identified
- Labs
- Optional
- Dietitian support
- Not included
Strengths
- LegitScript-certified (#50087439) — a genuine trust signal that is rare among compounders
- Physician-supervised care with a licensed-provider intake before anything ships
- Both molecules plus a rare oral GLP tablet, so needle-averse patients have a pathway
- Transparent monthly pricing with no insurance required
The other trade-offs
- Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven
- Brand tiers are pass-through, not a distinct in-house program
- The states it serves are not published, so confirm eligibility before starting
Before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Where this sits on the board
HealthRX is one of 24 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Funding & disclosures
- A number of links are affiliate or referral links.
- Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
- What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
- Full detail: disclosure page.